Commercial Sanofi acquires Translate Bio for $3.2B with renewed push...

Sanofi acquires Translate Bio for $3.2B with renewed push on mRNA technology

-

French pharmaceutical giant, Sanofi, in an attempt to “unlock the potential of mRNA”, has announced to acquire Massachusetts-based mRNA therapeutics firm, Translate Bio, for $3.2 billion.  

This particular announcement was made by the company a month after it had reported to have invested about $500 million in the mRNA technology which has also made its competitors Pfizer’s and Moderna’s COVID-19 vaccines to touch new heights of success.  

Sanofi collaboration with the firm aims at developing mRNA-based COVID-19 vaccines also targeting some other strategic areas. Being one of the world’s biggest drugmakers, it has failed to bring efficient COVID-19 shots in the market expediently, comparing with its relative upstarts BioNTech (partnering with Pfizer) and Moderna.

This acquisition would boost up Sanofi’s existing projects, as told by the CEO, Paul Hudson. He said, “Our goal is to unlock the potential of mRNA in other strategic areas such as immunology, oncology, and rare diseases in addition to vaccines.”  

Unlike other conventional vaccines, where a tiny amount of disease-causing organism are injected into the body stimulating body’s immune response, mRNA-based vaccines introduce genetic material into the body which helps the body to make its own safe components to train the immune system.    

The collaboration between the two, that began in June, 2018, rendered two mRNA-based vaccines (for COVID and Influenza) which are in their early stage clinical trials, expecting results by the third or fourth quarter of this year.   

The U.S. based firm, Translate Bio, also has some other treatments in its early stage pipeline, including drugs for Cystic Fibrosis and rare lung diseases. The company is now delving into ways in which its mRNA technology can be implemented in treatments for liver diseases and cancer.

The deal between the two companies will expedite the establishment of Sanofi mRNA Center of Excellence. According to Ronald Renaud, CEO of Translate Bio, with the expertise of Sanofi in the development of vaccines, the firm’s mRNA technology “is now even better positioned to reach more people, faster.”  

The said technology isn’t new but couldn’t successfully be brought into the market until Pfizer, Moderna and BioNTech made their first move during the COVID-19 pandemic. The successfulness of the technology has already convinced giant pharmas like GSK and Pfizer to exploit it for the treatments of HIV, Influenza (flu), cancer and genital herpes. 

Latest news

Zealand Pharma and Iktos collaborate to develop AI Technology for Peptide drug design

Specialists in artificial intelligence for new drug design, Iktos announced a research partnership with Zealand Pharma to...

UK’s NICE makes recommendation for Imlifidase by Hansa Biopharmaceutical

With the National Institute for Health and Care Excellence’s (NICE) recommendation for the use of imlifdase, over...

Heart failure drug by Cytokinetics delayed – FDA wants more time to review

The Food and Drug Administration requires more time to study Cytokinetics’ omecamtiv mecarbil following analysis of some...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you